TY - JOUR
T1 - Development of the Pediatric Restless Legs Syndrome Severity Scale (P-RLS-SS)©
T2 - A patient-reported outcome measure of pediatric RLS symptoms and impact
AU - Arbuckle, Robert
AU - Abetz, Linda
AU - Durmer, Jeffrey S.
AU - Ivanenko, Anna
AU - Owens, Judith A.
AU - Croenlein, Jens
AU - Bolton, Kate
AU - Moore, Adam
AU - Allen, Richard P.
AU - Walters, Arthur S.
AU - Picchietti, Daniel L.
N1 - Funding Information:
This project was supported by Boehringer Ingelheim Pharma . P-RLS-SS© Boehringer Ingelheim Pharma, 2010, all rights reserved.
PY - 2010/10
Y1 - 2010/10
N2 - Objective: To develop a questionnaire to measure Pediatric Restless Legs Syndrome (P-RLS) symptoms and impact for use in clinical research. Methods: Questionnaire items were developed based on open-ended, qualitative interviews of 33 children and adolescents diagnosed with definite RLS (ages 6-17 years) and their parents. The draft questionnaire was then tested through cognitive debriefing interviews with 21 of the same children/adolescents and 15 of their parents. This involved the children and parents answering the draft items and then interviewing them about the child's ability to understand and interpret the questionnaire. Expert clinicians provided clinical guidance throughout. Results: Draft severity questions were generated to measure the four-symptom and four-impact domains identified from the concept elicitation interviews: RLS sensations, move/rub due to RLS, relief from move/rub, pain, and impact of RLS on sleep, awake activities, emotions, and tiredness. RLS descriptions, symptoms, and impact were compared between those who had comorbid attention-deficit/hyperactivity disorder and those who did not. Revisions to several questions were made based on the cognitive debriefing interviews and expert clinician review, resulting in a severity scale with 17 morning and 24 evening items. Caution regarding self-administration in children ages 6-8 years is recommended. To complement the child/adolescent measures, a separate parent questionnaire was also developed. Conclusions: The P-RLS-SS was constructed based on detailed input from children and adolescents with RLS, their parents, and clinical experts, thus providing a scale with strong content validity that is intended to be comprehensive, clinically relevant, and important to patients. Validation of this scale is recommended.
AB - Objective: To develop a questionnaire to measure Pediatric Restless Legs Syndrome (P-RLS) symptoms and impact for use in clinical research. Methods: Questionnaire items were developed based on open-ended, qualitative interviews of 33 children and adolescents diagnosed with definite RLS (ages 6-17 years) and their parents. The draft questionnaire was then tested through cognitive debriefing interviews with 21 of the same children/adolescents and 15 of their parents. This involved the children and parents answering the draft items and then interviewing them about the child's ability to understand and interpret the questionnaire. Expert clinicians provided clinical guidance throughout. Results: Draft severity questions were generated to measure the four-symptom and four-impact domains identified from the concept elicitation interviews: RLS sensations, move/rub due to RLS, relief from move/rub, pain, and impact of RLS on sleep, awake activities, emotions, and tiredness. RLS descriptions, symptoms, and impact were compared between those who had comorbid attention-deficit/hyperactivity disorder and those who did not. Revisions to several questions were made based on the cognitive debriefing interviews and expert clinician review, resulting in a severity scale with 17 morning and 24 evening items. Caution regarding self-administration in children ages 6-8 years is recommended. To complement the child/adolescent measures, a separate parent questionnaire was also developed. Conclusions: The P-RLS-SS was constructed based on detailed input from children and adolescents with RLS, their parents, and clinical experts, thus providing a scale with strong content validity that is intended to be comprehensive, clinically relevant, and important to patients. Validation of this scale is recommended.
KW - Attention-deficit/hyperactivity disorder
KW - Children
KW - Patient-reported outcome
KW - Quality of life
KW - Questionnaire development
KW - Restless legs syndrome
KW - Sleep disorder
KW - Symptoms
UR - http://www.scopus.com/inward/record.url?scp=79952929324&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952929324&partnerID=8YFLogxK
U2 - 10.1016/j.sleep.2010.03.016
DO - 10.1016/j.sleep.2010.03.016
M3 - Article
C2 - 20801715
AN - SCOPUS:79952929324
SN - 1389-9457
VL - 11
SP - 897
EP - 906
JO - Sleep Medicine
JF - Sleep Medicine
IS - 9
ER -